Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 in Indolent Lymphoma
NCT00081809Phase 2Completed
- Sponsor
- Agenus Inc.
- Start
- Mar 2000
- Primary completion
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vitespen in follicular lymphoma (FL), small lymphocytic lymphoma (SLL), extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), sponsored by Agenus Inc.. Started Mar 2000; status: completed.
02
Drugs
vitespen
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)extranodal marginal zone lymphoma of mucosa-associated lymphoid tissueWaldenstrom macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00081809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081809.